Latest news
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - MorningstarMorningstar · Mon, 10 Aug 2026 11:00:00 GMTTreatment Options for Perimenopause Symptoms Are Emerging - MedscapeMedscape · Fri, 31 Jul 2026 11:15:22 GMT